Anixa Biosciences Inc. Overview

Anixa Biosciences, Inc., a biotechnology company operating within the Health Care sector, specializes in developing diagnostics and therapeutics for cancer detection. The company serves clients primarily in the United States and maintains its online presence through its website, www.anixa.com . Anixa Biosciences went public on the Nasdaq stock exchange in 1987.

Recent Stock Performance

As of May 29, 2025, Anixa Biosciences’ stock closed at $2.57. Over the past year, the stock has experienced significant fluctuations, with a 52-week high of $4.20 on November 7, 2024, and a 52-week low of $2.07 on January 13, 2025. The most recent price movement places the stock at $2.50.

Financial Metrics

The company’s market capitalization stands at $83,710,000 USD. Anixa Biosciences’ price-to-earnings (P/E) ratio is currently -6.68, indicating that the company is not generating positive earnings. Additionally, the price-to-book (P/B) ratio is 4.69, suggesting a notable difference between its market value and book value. These financial metrics highlight the need for a deeper analysis of the company’s financial health and market position.

Conclusion

Anixa Biosciences Inc. continues to focus on its core mission of developing cancer diagnostics and therapeutics. However, the recent stock price movements and financial ratios suggest that investors and analysts may need to conduct further evaluations to gain a comprehensive understanding of the company’s current standing in the market.